Discounted Cash Flow
Adapthealth Corp.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2018 | $345.3m | $24.3m | $68.4m | 7.0% | $-0.13 |
| 2019 | $529.6m (53.4%) | $-12.9m (-152.9%) | $60.4m (-11.7%) | -2.4% (-134.5%) | $0.86 (761.0%) |
| 2020 | $1.1b (99.5%) | $-58.7m (-355.7%) | $195.6m (223.8%) | -5.6% (-128.5%) | $-3.08 (-458.5%) |
| 2021 | $2.5b (132.4%) | $158.2m (369.3%) | $275.7m (40.9%) | 6.4% (215.9%) | $1.12 (136.4%) |
| 2022 | $3.0b (21.0%) | $73.1m (-53.8%) | $373.9m (35.6%) | 2.5% (-61.8%) | $0.47 (-58.0%) |
| 2023 | $3.2b (7.7%) | $-674.8m (-1022.7%) | $480.7m (28.6%) | -21.1% (-956.5%) | $-5.06 (-1176.6%) |
| 2024 | $3.3b (1.9%) | $94.8m (114.0%) | $541.8m (12.7%) | 2.9% (113.8%) | $0.62 (112.3%) |
| 2025 | $3.2b (-0.5%) | $-66.0m (-169.7%) | $601.8m (11.1%) | -2.0% (-170.0%) | $-0.52 (-183.9%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.